Poland· PL-100396035

Elebrato Ellipta

A vilanterol, umeclidinium bromid und fluticason furoat product containing fluticasoni furoas + umeklidynium + vilanterolum, registered in Poland by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 11 of our 19 countries.

ATC R03AL08

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedElebrato ElliptaATCR03AL08REGISTER NO.PL-100396035PACKS LISTED3CHECKEDSeptember 27, 2026

Where it is registered

Vilanterol, umeclidinium bromid und fluticason furoat is registered in 11 of 19 countries.

Countries holding a registration under ATC R03AL08 (vilanterol, umeclidinium bromid und fluticason furoat), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose

Vilanterol, umeclidinium bromid und fluticason furoat · ATC R03AL08

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Fluticasoni furoas + Umeklidynium + Vilanterolum
Manufacturer
GlaxoSmithKline Trading Services Limited
Country
Poland (PL)
ATC code
R03AL08
ATC class
Vilanterol, Umeclidinium bromid und Fluticason furoat
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909991350659
  • gtin
    05909991350666
  • gtin
    05909991350673

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ef032134-2030-4e51-8954-c0267fd523c2
GET /v1/drugs/ef032134-2030-4e51-8954-c0267fd523c2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do inhalacji, podzielony",
  "source": "urpl",
  "strength": "(92 mcg + 55 mcg + 22 mcg)/dawkę inh.",
  "packaging": "05909991350659 ¦ Rp ¦ EU/1/17/1237/001 ¦ 125059\n1 inhalator 14 dawek\n05909991350666 ¦ Rp ¦ EU/1/17/1237/002 ¦ 125060\n1 inhalator 30 dawek\n05909991350673 ¦ Rp ¦ EU/1/17/1237/003 ¦ 125061\n3 inhalatory 30 dawek",
  "substance": "Fluticasoni furoas 92 mcg + Umeclidinium 55 mcg + Vilanterolum 22 mcg",
  "common_name": "Fluticasoni furoas + Umeklidynium + Vilanterolum",
  "pl_product_id": "100396035",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about vilanterol, umeclidinium bromid und fluticason furoat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.